[{"id":"9b6d2eed-f184-4f87-922b-5c6538efff81","acronym":"T2317","url":"https://clinicaltrials.gov/study/NCT03712397","created_at":"2021-01-18T18:11:54.775Z","updated_at":"2024-07-02T16:35:50.946Z","phase":"Phase 2","brief_title":"Nanoliposomal Irinotecan in Head \u0026 Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy","source_id_and_acronym":"NCT03712397 - T2317","lead_sponsor":"National Health Research Institutes, Taiwan","biomarkers":" UGT1A1 • UGT1A9","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • UGT1A9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-04-11"},{"id":"42ffc1a1-34a8-4b3d-8410-01b3b6a6a637","acronym":"","url":"https://clinicaltrials.gov/study/NCT03557658","created_at":"2021-05-07T15:53:05.897Z","updated_at":"2024-07-02T16:36:29.541Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment","source_id_and_acronym":"NCT03557658","lead_sponsor":"Theracos","biomarkers":" UGT1A9","pipe":"","alterations":" ","tags":["UGT1A9"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/26/2018","start_date":" 07/26/2018","primary_txt":" Primary completion: 12/26/2018","primary_completion_date":" 12/26/2018","study_txt":" Completion: 12/26/2018","study_completion_date":" 12/26/2018","last_update_posted":"2021-06-03"},{"id":"f1d22181-40e4-400d-b33f-ac11370fd92c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185690","created_at":"2021-01-18T10:11:52.507Z","updated_at":"2025-02-25T15:41:44.886Z","phase":"Phase 1","brief_title":"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung","source_id_and_acronym":"NCT02185690","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • KRAS • ALK • UGT1A1 • CYP1A2 • UGT1A9","pipe":" | ","alterations":" KRAS mutation • ALK rearrangement • EGFR wild-type","tags":["EGFR • KRAS • ALK • UGT1A1 • CYP1A2 • UGT1A9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK rearrangement • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Mektovi (binimetinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/11/2018","start_date":" 01/11/2018","primary_txt":" Primary completion: 07/04/2019","primary_completion_date":" 07/04/2019","study_txt":" Completion: 07/04/2019","study_completion_date":" 07/04/2019","last_update_posted":"2021-04-02"}]